The results of a one-year, open multicenter trial of perphenazine enanthate, a sustained-release neuroleptic drug, are reported. 240 patients (62% suffering from schizophrenia) were included in the study and 144 were followed during the 12-month period. The usual adverse reactions associated with sustained-release neuroleptic drugs were observed.
View Article and Find Full Text PDFAnn Med Psychol (Paris)
October 1971
Ann Med Leg Criminol Police Sci Toxicol
December 1996
Ann Med Psychol (Paris)
January 1962
Med Exp Int J Exp Med
November 1998
Ann Med Psychol (Paris)
April 1960
Ann Med Psychol (Paris)
February 1960